113 related articles for article (PubMed ID: 7105580)
1. Mechanisms of lytic and blastic metastatic disease of bone.
Galasko CS
Clin Orthop Relat Res; 1982 Sep; (169):20-7. PubMed ID: 7105580
[TBL] [Abstract][Full Text] [Related]
2. The development of skeletal metastases.
Galasko CS
Nihon Seikeigeka Gakkai Zasshi; 1989 May; 63(5):667-76. PubMed ID: 2794640
[TBL] [Abstract][Full Text] [Related]
3. The pathological basis for skeletal scintigraphy.
Galasko CS
J Bone Joint Surg Br; 1975 Aug; 57(3):353-9. PubMed ID: 1158946
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
5. Bone metastases studied by experimental models.
Galasko CS
Schweiz Med Wochenschr; 1981 Dec; 111(49):1862-8. PubMed ID: 7330640
[No Abstract] [Full Text] [Related]
6. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.
Wise-Milestone L; Akens MK; Rosol TJ; Hojjat SP; Grynpas MD; Whyne CM
J Orthop Res; 2012 May; 30(5):817-23. PubMed ID: 22025272
[TBL] [Abstract][Full Text] [Related]
9. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
[TBL] [Abstract][Full Text] [Related]
10. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
13. An in vivo model of prostate carcinoma growth and invasion in bone.
Fisher JL; Schmitt JF; Howard ML; Mackie PS; Choong PF; Risbridger GP
Cell Tissue Res; 2002 Mar; 307(3):337-45. PubMed ID: 11904770
[TBL] [Abstract][Full Text] [Related]
14. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
15. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y
Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
17. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
18. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
Clines GA; Guise TA
Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
[TBL] [Abstract][Full Text] [Related]
19. Canine prostate stimulates osteoblast function using the endothelin receptors.
LeRoy BE; Sellers RS; Rosol TJ
Prostate; 2004 May; 59(2):148-56. PubMed ID: 15042615
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
